Pfizer (BUE:PFE) Beneish M-Score: -2.32 (As of Jun. 24, 2026)


BUE:PFE Pfizer Inc BUE:PFE
58 GF Score
Price ARS9,620.00
GF Value ARS10,141.47
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Pfizer Beneish M-Score?

Pfizer BUE:PFE +0.63% 58 Beneish M-Score is -2.32 as of Jun. 24, 2026. GuruFocus rates BUE:PFE with a GF Score™ of 58/100 and a GF Value™ of ARS10,141.47 (Fairly Valued). The stock has 5 warning signs investors should review. Among 911 Drug Manufacturers companies, Pfizer ranks worse than 63.34% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.32 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Pfizer's Beneish M-Score or its related term are showing as below:

BUE:PFE' s Beneish M-Score Range Over the Past 10 Years
Min: -2.72   Med: -2.42   Max: -1.92
Current: -2.32

During the past 13 years, the highest Beneish M-Score of Pfizer was -1.92. The lowest was -2.72. And the median was -2.42.


Pfizer Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Pfizer's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pfizer Beneish M-Score Chart

Pfizer Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.06 -2.30 -2.30 -2.65 -2.31

Pfizer Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.61 -2.52 -2.43 -2.31 -2.32

BUE:PFE vs GILD, BMY, AMGN: Beneish M-Score Comparison

For the Drug Manufacturers - General subindustry, Pfizer's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pfizer Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pfizer's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Pfizer's Beneish M-Score falls into.


BUE:PFE
58GF Score
Pfizer Inc BUE:PFE
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pfizer Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Pfizer for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0287+0.528 * 0.9849+0.404 * 1.0129+0.892 * 1.3985+0.115 * 1.0397
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9508+4.679 * 0.010004-0.327 * 1.0118
=-2.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ARS22,613,818 Mil.
Revenue was 20204641.558 + 25483792.166 + 22616338.546 + 17396528.174 = ARS85,701,300 Mil.
Gross Profit was 15243667.977 + 17831542.22 + 16950710.804 + 12911161.12 = ARS62,937,082 Mil.
Total Current Assets was ARS59,875,651 Mil.
Total Assets was ARS290,300,849 Mil.
Property, Plant and Equipment(Net PPE) was ARS27,128,751 Mil.
Depreciation, Depletion and Amortization(DDA) was ARS8,890,302 Mil.
Selling, General, & Admin. Expense(SGA) was ARS18,562,330 Mil.
Total Current Liabilities was ARS48,026,922 Mil.
Long-Term Debt & Capital Lease Obligation was ARS83,670,986 Mil.
Net Income was 3757084.558 + -2392053.853 + 4808721.916 + 3454848.631 = ARS9,628,601 Mil.
Non Operating Income was -760645.329 + -6945374.809 + -2280102.823 + -268314.705 = ARS-10,254,438 Mil.
Cash Flow from Operations was 3656410.912 + 7762563.109 + 6250931.087 + -690969.726 = ARS16,978,935 Mil.
Total Receivables was ARS15,718,715 Mil.
Revenue was 14620696.595 + 17941640.179 + 16824799.761 + 11894926.33 = ARS61,282,063 Mil.
Gross Profit was 11587821.509 + 11973550.12 + 11822318.48 + 8939776.372 = ARS44,323,466 Mil.
Total Current Assets was ARS48,889,520 Mil.
Total Assets was ARS221,765,532 Mil.
Property, Plant and Equipment(Net PPE) was ARS19,558,580 Mil.
Depreciation, Depletion and Amortization(DDA) was ARS6,751,996 Mil.
Selling, General, & Admin. Expense(SGA) was ARS13,959,893 Mil.
Total Current Liabilities was ARS38,859,178 Mil.
Long-Term Debt & Capital Lease Obligation was ARS60,572,219 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(22613817.849 / 85701300.444) / (15718714.641 / 61282062.865)
=0.263868 / 0.256498
=1.0287

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(44323466.481 / 61282062.865) / (62937082.121 / 85701300.444)
=0.72327 / 0.734377
=0.9849

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (59875651.268 + 27128751.247) / 290300849.21) / (1 - (48889519.983 + 19558579.689) / 221765531.998)
=0.700296 / 0.691349
=1.0129

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=85701300.444 / 61282062.865
=1.3985

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(6751995.688 / (6751995.688 + 19558579.689)) / (8890301.826 / (8890301.826 + 27128751.247))
=0.256627 / 0.246822
=1.0397

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(18562329.795 / 85701300.444) / (13959893.316 / 61282062.865)
=0.216593 / 0.227797
=0.9508

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((83670986.219 + 48026922.37) / 290300849.21) / ((60572218.779 + 38859178.439) / 221765531.998)
=0.45366 / 0.448363
=1.0118

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(9628601.252 - -10254437.666 - 16978935.382) / 290300849.21
=0.010004

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Pfizer has a M-score of -2.04 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.32 mean?
Pfizer (BUE:PFE) has a Beneish M-Score of -2.32 as of Jun. 24, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Pfizer and its competitors. According to the industry distribution chart, Pfizer ranks #577 out of 911 companies in the Drug Manufacturers industry, placing it in the top 63.3%.
Is Pfizer's Beneish M-Score too high?
Pfizer's current Beneish M-Score is -2.32. Based on the distribution chart, Pfizer ranks #577 out of 911 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Pfizer has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pfizer's Beneish M-Score compare to GILD and BMY?
According to the Drug Manufacturers industry distribution chart, Pfizer ranks #577 out of 911 companies for Beneish M-Score. This places Pfizer in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Pfizer and its competitors. Pfizer's current Beneish M-Score is -2.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pfizer stock overvalued right now?
Based on GuruFocus' analysis, Pfizer (BUE:PFE) is currently considered Fairly Valued. The stock's GF Value™ is ARS10,141.47, compared to a current price of ARS9,620.00 — trading 5.1% below its estimated fair value. The current Beneish M-Score is -2.32. Pfizer's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Pfizer (BUE:PFE), the current Beneish M-Score is -2.32 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pfizer (BUE:PFE) Overvalued in 2026?

Based on GuruFocus' analysis, Pfizer stock appears to be undervalued. The current stock price of ARS9,620.00 is trading 5.1% below its estimated GF Value™ of ARS10,141.47. GuruFocus considers Pfizer to be Fairly Valued.

Key valuation signals for BUE:PFE:

  • Beneish M-Score: -2.32
  • GF Value™: ARS10,141.47 vs. price of ARS9,620.00 (5.1% below fair value)
  • GF Score™: 58/100 with 5 warning signs

No single metric tells the full story. See the BUE:PFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pfizer Business Description

Address 66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
58GF Score

Get the complete analysis for BUE:PFE

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS9,620.00
Price
ARS10,141.47
GF Value